Professional Marketing briefs: April 2013

Oncology lifts Roche's Q1, Lucentis finds new fans
Oncology lifts Roche's Q1, Lucentis finds new fans

Mylan has acquired Strides Arcolab's Indian injectable manufacturer Agila Specialties for $1.6 billion. This will expand Mylan's presence in emerging markets as well as add 200 marketable products to its portfolio, bringing the company's total to 700. Leerink Swann analyst Jason Gerberry estimates that the acquisition will add 4% to Mylan's 2014 earnings.

Privately held ­Royalty Pharma, which typically buys intellectual property rights, such as those for Amgen's Neupogen, is looking to enter the manufacturing side of the business with its $6.5-billion proposal to buy Ireland-based Élan. The announcement follows weeks of rejiggering at Élan, which announced February 6 that it sold its 50% ownership in the MS drug Tysabri for $3.25 billion to Biogen Idec.

Roche plans to slash the cost of its cancer therapy Herceptin in India. According to Fierce­Pharma, the cost for the drug, which will be made by Emcure Pharmaceuticals, will drop from around $2,000 a month to $1,366 a month. India's patent-resistance has been a source of industry friction—the country has honored industry patents for just over three decades, a 2012 Economist report says.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.